Cencora, Inc. (COR) stock
CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3021% above fair value
$350.56−6.38 (-1.79%)
Close on Nov 17, 2026Market cap $66.90BP/E 26.0Yield 0.63%
Cencora revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cencora's revenue for the twelve months ending Jun 30, 2026 was $332.77B, up 5.1% year over year. For fiscal 2025 it was $321.33B, up 9.3% from the year before. Over ten years it grew 9.0% a year on average. The highest annual figure on record is $321.33B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $321.33B | +9.3% |
| FY2024 | Sep 30, 2024 | $293.96B | +12.1% |
| FY2023 | Sep 30, 2023 | $262.17B | +9.9% |
| FY2022 | Sep 30, 2022 | $238.59B | +11.5% |
| FY2021 | Sep 30, 2021 | $213.99B | +12.7% |
| FY2020 | Sep 30, 2020 | $189.89B | +5.7% |
| FY2019 | Sep 30, 2019 | $179.59B | +6.9% |
| FY2018 | Sep 30, 2018 | $167.94B | +9.7% |
| FY2017 | Sep 30, 2017 | $153.14B | +4.3% |
| FY2016 | Sep 30, 2016 | $146.85B | +8.0% |
| FY2015 | Sep 30, 2015 | $135.96B | +13.7% |
| FY2014 | Sep 30, 2014 | $119.57B | +35.9% |
| FY2013 | Sep 30, 2013 | $87.96B | +12.7% |
| FY2012 | Sep 30, 2012 | $78.08B | -0.8% |
| FY2011 | Sep 30, 2011 | $78.70B | +1.2% |
| FY2010 | Sep 30, 2010 | $77.78B | +8.4% |
| FY2009 | Sep 30, 2009 | $71.76B | +2.2% |
| FY2008 | Sep 30, 2008 | $70.19B | +6.9% |
| FY2007 | Sep 30, 2007 | $65.67B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $84.75B | +5.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $78.36B | +3.8% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $85.93B | +5.5% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $83.73B | +5.9% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $80.66B | +8.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $75.45B | +10.3% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $81.49B | +12.8% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $79.05B | +14.7% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $74.24B | +10.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $68.41B | +7.8% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $72.25B | +15.0% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $68.92B | +12.7% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $66.95B | +11.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $63.46B | +9.9% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $62.85B | +5.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $61.17B | +3.8% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $60.06B | +12.5% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $57.72B | +17.4% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $59.63B | +13.5% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $58.91B | +19.6% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $53.41B | +17.7% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $49.15B | +3.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $52.52B | +9.7% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $49.24B | +7.9% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $45.37B | +0.3% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $47.42B | +9.5% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $47.86B | +5.4% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $45.64B | +5.4% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $45.24B | +4.9% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $43.32B | +5.6% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $45.39B | +12.2% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $43.30B | +10.7% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $43.14B | +11.5% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $41.03B | +10.5% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $40.47B | +6.0% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $39.12B | +4.2% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $38.71B | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $37.15B | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $38.17B | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $37.56B | – |
See a number that looks wrong?